RESprotect
RESprotect GmbH is a Dresden-based biotech company specializing in developing drugs to prevent and treat chemotherapeutic drug resistance and radiation therapy resistance. Their first product candidate, RP101, is an oral small molecule drug that has shown to significantly improve survival in advanced pancreatic cancer patients by enhancing chemosensitivity and preventing resistance through its interaction with heat shock protein 27 (Hsp27). The company has received multiple awards, including the Fraunhofer-Award, futureSAX award, IQ innovation award, and European Orphan Drug Designation for RP101. They are engaged in clinical development, strategic partnerships, and have a focus on innovative cancer therapies.
Industries
Nr. of Employees
small (1-50)
Products
RP101 (small-molecule nucleoside analogue)
Orally administered nucleoside small molecule developed as an adjunct to chemotherapy to bind and suppress Hsp27, with the objective of preventing chemotherapy-induced resistance and improving chemosensitivity; investigated in pancreatic cancer and reported at Phase IIb clinical stage.
Second-generation nucleoside derivatives (lead candidates)
Follow-on derivatives of the lead nucleoside scaffold designed to increase potency and resistance-preventing effects in standard screens; reported examples were up to tenfold more potent than the lead in screening systems.
RP101
(E)-5-(2-bromovinyl)-deoxyuridine (RP101) is a 2´-deoxyuridine derivative, which is a thymidine analogue and lead substance targeting heat shock protein Hsp27 to prevent chemoresistance.
RP525
Second generation derivative of RP101 designed for enhanced resistance-preventing effects and significantly increased potency targeting heat shock protein Hsp27.
RP7101
Second generation derivative of RP101 designed for enhanced resistance-preventing effects and significantly increased potency targeting heat shock protein Hsp27.
RP656
Second generation derivative of RP101 designed for enhanced resistance-preventing effects and significantly increased potency targeting heat shock protein Hsp27.
RP101 (small-molecule nucleoside analogue)
Orally administered nucleoside small molecule developed as an adjunct to chemotherapy to bind and suppress Hsp27, with the objective of preventing chemotherapy-induced resistance and improving chemosensitivity; investigated in pancreatic cancer and reported at Phase IIb clinical stage.
Second-generation nucleoside derivatives (lead candidates)
Follow-on derivatives of the lead nucleoside scaffold designed to increase potency and resistance-preventing effects in standard screens; reported examples were up to tenfold more potent than the lead in screening systems.
RP101
(E)-5-(2-bromovinyl)-deoxyuridine (RP101) is a 2´-deoxyuridine derivative, which is a thymidine analogue and lead substance targeting heat shock protein Hsp27 to prevent chemoresistance.
RP525
Second generation derivative of RP101 designed for enhanced resistance-preventing effects and significantly increased potency targeting heat shock protein Hsp27.
RP7101
Second generation derivative of RP101 designed for enhanced resistance-preventing effects and significantly increased potency targeting heat shock protein Hsp27.
RP656
Second generation derivative of RP101 designed for enhanced resistance-preventing effects and significantly increased potency targeting heat shock protein Hsp27.
Services
Collaborative agreements to co-develop and license oncology drug candidates and to manage regional rights for clinical progression and commercialization.
Discovery and validation of targets related to chemoresistance and execution of preclinical screening and animal efficacy studies to advance small-molecule candidates into clinical development.
Collaborative agreements to co-develop and license oncology drug candidates and to manage regional rights for clinical progression and commercialization.
Discovery and validation of targets related to chemoresistance and execution of preclinical screening and animal efficacy studies to advance small-molecule candidates into clinical development.
Expertise Areas
- Chemogenomics-driven target discovery
- Target validation and mechanism-of-action studies
- Proteomics and biomarker discovery
- Medicinal chemistry and lead optimization of nucleoside analogues
Key Technologies
- Chemogenomics
- Proteomics
- Nucleoside small-molecule chemistry
- In vitro cytotoxicity and resistance assays
News & Updates
RESprotect announces that it has received back the North-American rights for RP101 from its former partner and has gained approval from German Authorities for the development plan of RP101, aiming to proceed into a pivotal phase IIb study in late-stage pancreatic cancer patients.
RESprotect was awarded by the German Federal Ministry of Economics and Technology at the Technology Competition “Trusted Cloud” in March 2011.
RESprotect GmbH was nominated as a finalist of the STEP Award 2010.
In January 2010, RP101 was granted the Orphan Drug designation for pancreatic cancer by the European Medicines Agency (EMA).
RESprotect was assigned SME status by the European Medicines Agency (EMA) in October 2009, benefiting from provisions for assistance.
A study published in the Journal of Cancer Research and Clinical Oncology shows that RP101 binds to heat shock protein HSP27 and improves survival in animals and pancreatic cancer patients.
RESprotect announces that it has received back the North-American rights for RP101 from its former partner and has gained approval from German Authorities for the development plan of RP101, aiming to proceed into a pivotal phase IIb study in late-stage pancreatic cancer patients.
RESprotect was awarded by the German Federal Ministry of Economics and Technology at the Technology Competition “Trusted Cloud” in March 2011.
RESprotect GmbH was nominated as a finalist of the STEP Award 2010.
In January 2010, RP101 was granted the Orphan Drug designation for pancreatic cancer by the European Medicines Agency (EMA).
RESprotect was assigned SME status by the European Medicines Agency (EMA) in October 2009, benefiting from provisions for assistance.
A study published in the Journal of Cancer Research and Clinical Oncology shows that RP101 binds to heat shock protein HSP27 and improves survival in animals and pancreatic cancer patients.